Form 4: 180 Life Sciences Accelerates Vesting of Chief Accounting Officer's Stock Options

180 Life Sciences Corp. has accelerated the vesting of 25,000 non-qualified stock options for its Chief Accounting Officer, Eric R. Van Lent, subject to stockholder approval of the company's 2025 Option Incentive Plan.

Summary

• Eric R. Van Lent, Chief Accounting Officer of 180 Life Sciences Corp. (ATNF), reported changes in his beneficial ownership.
• As of July 12, 2025, Mr. Van Lent directly owns 8,174 shares of Common Stock.
• He holds 25,000 non-qualified stock options to buy Common Stock at an exercise price of $0.929, with an expiration date of June 17, 2035.
• The Board of Directors, upon recommendation from the Compensation Committee, approved the accelerated vesting of all 25,000 options effective July 12, 2025.
• Originally, these options were set to vest in two equal tranches on December 17, 2025, and June 17, 2026.
• The accelerated options cannot be exercised until stockholder approval is obtained for the Company's 2025 Option Incentive Plan.
• If stockholder approval for the 2025 Option Incentive Plan is not obtained, the outstanding options will be cancelled.

Sentiment

Score: 6

Explanation: The accelerated vesting is a positive for executive incentive and retention, but the significant condition of stockholder approval introduces uncertainty, preventing a higher score.

Positives

• Accelerated vesting of stock options for the Chief Accounting Officer may serve as a strong incentive for executive retention and alignment with shareholder interests.
• The direct ownership of 8,174 common shares by the Chief Accounting Officer indicates a personal stake in the company's performance.

Negatives

• The accelerated vesting of options is conditional and subject to stockholder approval of the 2025 Option Incentive Plan, introducing uncertainty regarding their ultimate realization.
• If stockholder approval is not secured, the 25,000 options will be cancelled, negating the intended benefit.

Risks

• The primary risk is the failure to obtain stockholder approval for the Company's 2025 Option Incentive Plan, which would result in the cancellation of the 25,000 accelerated options.
• Potential dilution for existing shareholders if the 2025 Option Incentive Plan is approved and the options are exercised.

Future Outlook

The future outlook for the accelerated options is contingent upon obtaining stockholder approval for the Company's 2025 Option Incentive Plan. Without this approval, the options will be cancelled.

Management Comments

• The Board of Directors, with the recommendation of the Compensation Committee, approved the accelerated vesting of all options effective July 12, 2025.

Industry Context

This filing pertains to an internal corporate governance and executive compensation decision, rather than broader industry trends. It reflects the company's approach to incentivizing its key officers.

Comparison to Industry Standards

• Accelerated vesting of executive stock options is a common practice in the biotechnology and life sciences sectors, often used to retain key talent or as a performance incentive.
• The condition of stockholder approval for a new option incentive plan is standard corporate governance practice to ensure alignment with shareholder interests and prevent excessive dilution.

Corporate Governance

Stakeholder Impact

• Shareholders: Will need to vote on the 2025 Option Incentive Plan, which could lead to dilution if approved and options are exercised. The accelerated vesting could also be seen as a positive for management alignment.
• Employees (specifically the Chief Accounting Officer): Directly benefits from the accelerated vesting, subject to the plan's approval, which enhances his compensation and incentive structure.

Next Steps

• The company must seek and obtain stockholder approval for its 2025 Option Incentive Plan for the accelerated options to become exercisable and avoid cancellation.

Key Dates

Keywords

180 Life Sciences Corp, ATNF, SEC Form 4, beneficial ownership, stock options, accelerated vesting, executive compensation, Chief Accounting Officer, corporate governance, incentive plan